Travere therapeutics announces positive topline results from cohort 6 in the phase 1/2 compose study of pegtibatinase in classical homocystinuria

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline

TVTX Ratings Summary

TVTX Quant Ranking